Medivation Stock Hits New 52-Week High (MDVN)

NEW YORK ( TheStreet) -- Medivation (Nasdaq: MDVN) hit a new 52-week high Friday as it is currently trading at $90.59, above its previous 52-week high of $90.40 with 497,727 shares traded as of 2:05 p.m. ET. Average volume has been 753,800 shares over the past 30 days.

Medivation has a market cap of $3.22 billion and is part of the health care sector and drugs industry. Shares are up 87.4% year to date as of the close of trading on Thursday.

Medivation, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe.

TheStreet Ratings rates Medivation as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including poor profit margins, weak operating cash flow and generally poor debt management. You can view the full Medivation Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Component Stocks Rise After Trump Reverses Decision on ZTE

Component Stocks Rise After Trump Reverses Decision on ZTE